Abstract Library

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ćwikla J

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,

Keywords: NENs, PRRT, Hindgut, CUP,

#2256 Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms

Introduction: Tumor growth and the ability to metastasize is a multistage process involving interactions between cancer cells and the vascular endothelium. These interactions have been reported to be mediated by various molecules including sVCAM-1. We have previously shown elevated serum concentration of sVCAM-1 in 82 neuroendocrine neoplasms (NEN) compared to controls. Here, we present results of the extension of the previous study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Malczewska A

Authors: Rosiek V, Malczewska A, Kos-Kudła B,

Keywords: neuroendocrine neoplasms, adhesion molecule, metastasis,

#1847 CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro

Introduction: Neuroendocrine tumors (NETs) overexpress CXCR4. We have previously shown that stimulation of CXCR4 by its ligand SDF-1 promotes the epithelial-mesenchymal transition (EMT) and increases distant tumor spread. Ulocuplumab (Ulo) is a fully human IgG4 mAb designed to inhibit the binding of CXCR4 to SDF-1.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Quaresmini D

Authors: Quaresmini D, Cives M, Pellè E, Ungaro A, Felici C,

Keywords: pNET, CXCR4, EMT, Ulocuplumab,

#1692 A Case Report of NET G1 of the Gallbladder

Introduction: The SEER database has shown that gallbladder NET is 0.5% of all NET cases, and G1 cases are limited to 2% in the rare gallbladder NET cases.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nakano K, Masui T, Uchida Y, Sato A, Sasaki N,

Keywords: NET G1, gallbladder,